<DOC>
	<DOCNO>NCT01165138</DOCNO>
	<brief_summary>The purpose study compare efficacy safety fluticasone furoate/vilanterol ( GW642444 ) inhalation powder fluticasone furoate inhalation powder administer daily adolescent adult subject 12 year age old persistent bronchial asthma 12 week treatment period .</brief_summary>
	<brief_title>Study HZA106827 : Efficacy/Safety Study Fluticasone Furoate/Vilanterol ( GW642444 ) Adult Adolescent Asthmatics</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Fluticasone</mesh_term>
	<criteria>Outpatients least 12 year age Male female ; female subject childbearing potential must willing use birth control Prebronchodilator FEV1 4090 % predict normal Reversibility FEV1 least 12 % 200mL Current asthma therapy include inhaled corticosteroid use least 12 week prior first visit History lifethreatening asthma last 10 year Respiratory infection oral candidiasis Asthma exacerbation require oral corticosteroid require overnight hospitalisation require additional asthma treatment Uncontrolled disease clinical abnormality Allergies study drug excipients Taking another investigational medication prohibit medication Night shift worker Current smoker subject smoke history least 10 pack year</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>GW642444</keyword>
	<keyword>Vilanterol</keyword>
	<keyword>Asthma</keyword>
	<keyword>Fluticasone Furoate</keyword>
</DOC>